0001209191-21-005254.txt : 20210125
0001209191-21-005254.hdr.sgml : 20210125
20210125205819
ACCESSION NUMBER: 0001209191-21-005254
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210121
FILED AS OF DATE: 20210125
DATE AS OF CHANGE: 20210125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROTE WILLIAM E.
CENTRAL INDEX KEY: 0001698262
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 21551450
MAIL ADDRESS:
STREET 1: C/O RETROPHIN, INC.
STREET 2: 3721 VALLEY CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-21
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001698262
ROTE WILLIAM E.
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, STE 300
SAN DIEGO
CA
92130
0
1
0
0
Senior Vice President, R&D
Common Stock
2021-01-21
4
A
0
15000
0.00
A
39582
D
Employee stock option (right to buy)
26.88
2021-01-21
4
A
0
57500
0.00
A
2031-01-20
Common Stock
57500
57500
D
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.
Includes 496 shares of the Issuer's common stock acquired by the reporting person on November 30, 2020 pursuant to an employee stock purchase program.
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2021-01-25